HC Wainwright Has Optimistic View of TSE:MSL FY2030 Earnings

Merus Labs International Inc. (TSE:MSL) (NASDAQ:MSLI) – HC Wainwright lifted their FY2030 earnings per share estimates for Merus Labs International in a note issued to investors on Monday, May 18th. HC Wainwright analyst A. He now anticipates that the specialty pharmaceutical company will post earnings per share of $0.48 for the year, up from their prior estimate of $0.47.

A number of other equities analysts have also recently issued reports on MSL. Guggenheim upgraded Merus Labs International to a “strong-buy” rating in a report on Tuesday, April 28th. Cantor Fitzgerald upgraded Merus Labs International to a “strong-buy” rating in a report on Wednesday, March 11th. Finally, Leerink Partners upgraded Merus Labs International to a “strong-buy” rating in a report on Monday, April 6th. Three investment analysts have rated the stock with a Strong Buy rating, According to data from MarketBeat, Merus Labs International has an average rating of “Strong Buy”.

Merus Labs International Price Performance

Merus Labs International has a 1-year low of C$0.95 and a 1-year high of C$1.76.

Merus Labs International Company Profile

Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates.